Bryostatin-1 Can Reverse Cognitive Decline in Moderate-to-Severe Alzheimer’s, New Data Shows

Bryostatin-1 Can Reverse Cognitive Decline in Moderate-to-Severe Alzheimer’s, New Data Shows
Neurotrope’s investigational compound Bryostatin-1 showed evidence of sustained improvement in cognition compared to placebo in patients with moderate-to-severe Alzheimer’s disease, according to additional results from a Phase 2 clinical trial. This beneficial effect was sustained for at least four weeks upon ending treatment and was even more pronounced in the absence of the therapy memantine (sold

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Pamela Allen says:

    I have heard there will be another clinical trial for this Byrostatin. My husband is in middle stage Alzheimer’s and I am very interested in him participating in the clinical trial. How do I find out about it? Thank you, Pam Allen

Leave a Comment

Your email address will not be published. Required fields are marked *